CN100347194C - 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用 - Google Patents

分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用 Download PDF

Info

Publication number
CN100347194C
CN100347194C CNB018228844A CN01822884A CN100347194C CN 100347194 C CN100347194 C CN 100347194C CN B018228844 A CNB018228844 A CN B018228844A CN 01822884 A CN01822884 A CN 01822884A CN 100347194 C CN100347194 C CN 100347194C
Authority
CN
China
Prior art keywords
antibody
cell
scfv
fragment
epi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018228844A
Other languages
English (en)
Chinese (zh)
Other versions
CN1649900A (zh
Inventor
J·拉扎罗维茨
Y·哈盖
D·普拉克辛
T·沃格尔
A·尼姆罗德
H·马－海姆
E·桑通
T·里希特
B·阿米特
L·库佩尔曼
T·佩雷茨
A·莱瓦农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of CN1649900A publication Critical patent/CN1649900A/zh
Application granted granted Critical
Publication of CN100347194C publication Critical patent/CN100347194C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB018228844A 2000-12-29 2001-12-31 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用 Expired - Fee Related CN100347194C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25894800P 2000-12-29 2000-12-29
US75118100A 2000-12-29 2000-12-29
US60/258,948 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
CN1649900A CN1649900A (zh) 2005-08-03
CN100347194C true CN100347194C (zh) 2007-11-07

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018228844A Expired - Fee Related CN100347194C (zh) 2000-12-29 2001-12-31 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用

Country Status (13)

Country Link
EP (1) EP1406930A4 (ja)
JP (1) JP2005503756A (ja)
KR (1) KR20030091953A (ja)
CN (1) CN100347194C (ja)
BR (1) BR0116764A (ja)
CA (1) CA2433225A1 (ja)
CZ (1) CZ20031982A3 (ja)
HU (1) HUP0700079A2 (ja)
IL (1) IL156689A0 (ja)
MX (1) MXPA03005945A (ja)
PL (1) PL366223A1 (ja)
RU (1) RU2003123101A (ja)
WO (1) WO2002053700A2 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
AU2003279657A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
AU2004259406A1 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
RU2006102571A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Специфические антитела человека
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
EP1751300B1 (en) * 2004-05-11 2017-11-08 AbGenomics Coöperatief U.A. T-cell death-inducing epitopes
US8980862B2 (en) 2010-11-12 2015-03-17 Gentium S.P.A. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD)
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
BR112014031934B1 (pt) 2012-06-22 2021-05-04 Gentium S.R.L. método com base em euglobulina para determinar a atividade biológica de defibrotide
WO2016013828A1 (ko) * 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
WO2019027034A1 (ja) * 2017-08-04 2019-02-07 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途
CN109929036A (zh) * 2017-12-19 2019-06-25 泰州迈博太科药业有限公司 一种表位特异的抗体筛选方法及所筛选到的抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3326693A (en) * 1991-12-12 1993-07-19 Scripps Research Institute, The Bifunctional antithrombotic molecules and antithrombotic polypeptides
EP0833650A4 (en) * 1995-06-14 2005-01-19 Gen Hospital Corp P-SELECTINE LIGANDS AND ASSOCIATED METHODS AND MOLECULES ---
EP0850243B1 (en) * 1995-08-03 2003-10-08 Board Of Regents Of The University Of Oklahoma o-glycan inhibitors of selectin mediated inflammation
CA2332563A1 (en) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptides and methods of synthesis and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Novel P-Selectin GlycoproteinLigand-1 MonoclonalAntibody Recognizes an Epitope Within Tyrosine SulfateMotif of Human PSGL-1 and Blocks Recognition of Both P-and L-Selectin. Karen R.Snapp.等.Blood,Vol.91 No.1. 1998 *

Also Published As

Publication number Publication date
BR0116764A (pt) 2007-01-09
KR20030091953A (ko) 2003-12-03
IL156689A0 (en) 2004-01-04
WO2002053700A3 (en) 2004-02-12
EP1406930A2 (en) 2004-04-14
CN1649900A (zh) 2005-08-03
HUP0700079A2 (en) 2007-05-02
JP2005503756A (ja) 2005-02-10
CA2433225A1 (en) 2002-07-11
WO2002053700A2 (en) 2002-07-11
EP1406930A4 (en) 2007-01-10
PL366223A1 (en) 2005-01-24
RU2003123101A (ru) 2005-03-10
MXPA03005945A (es) 2004-10-15
CZ20031982A3 (cs) 2004-09-15

Similar Documents

Publication Publication Date Title
CN100347194C (zh) 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用
CN108503708B (zh) 抗人cd47抗体及其用途
CN1165764C (zh) 抗psma抗体或其抗原结合部分，以及它们的用途
CN101076542A (zh) 特异性针对肝细胞癌和其他癌的抗体及其用途
CN1201005C (zh) 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
CN1602317A (zh) 血管生成素－2的特异结合剂
CN1922199A (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
CN1795009A (zh) 抗－cd33抗体和使用其治疗急性髓性白血病的方法
CN1413220A (zh) 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法
CN1826138A (zh) Rg1抗体及其用途
CN101044242A (zh) 肿瘤特异性抗体
CN1768076A (zh) 淀粉样β(1－42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
CN1950399A (zh) 免疫原性较弱的结合分子
CN1571797A (zh) 抗hla－dr抗体
CN102317316A (zh) 人抗α突触核蛋白自身抗体
CN1575303A (zh) 人cdr－移植抗体及其抗体片段
CN1925871A (zh) 聚合物结合的抗体癌症治疗剂
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CN1610743A (zh) 在乳腺癌和膀胱癌中差异表达的基因及编码的多肽
CN1684700A (zh) 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
CN1642983A (zh) 抗C5aR抗体及其应用
CN1551886A (zh) 用于选择性癌症治疗的特异性人抗体
CN1639185A (zh) 癌相关表位
CN1493597A (zh) 分离树突状细胞膜蛋白基因

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1082259

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1082259

Country of ref document: HK